Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences all participated in the funding. Proceeds will support the advancement of Opsona’s clinical trials targeting inflammatory diseases, such as rheumatoid arthritis, lupus and transplantation, the company said.
As part of the financing, Opsona Therapeutics also announced the addition of Florent Gros, managing director at Novartis Venture Fund, and Manus Rogan, managing partner at Fountain Healthcare Partners, to the board of directors. Opsona expects to make a number of other key appointments in the corporate and clinical areas in the coming months.
Opsona has also announced the opening of a new facility in Switzerland. The Swiss laboratory will carry out pivotal assay development and biochemical work for new projects and therapeutics recently acquired by Opsona to expand its pipeline of immunomodulators.
Mark Heffernan, CEO of Opsona, said: Completion of this financing represents a significant milestone in the transition of Opsona into a product-focused company delivering key clinical development milestones.
With the endorsement of our existing and new investors, including the Novartis Venture Fund, Fountain Healthcare Partners and Seroba Kernel Life Sciences, Opsona is positioned to deliver on proof of concept studies in patients by targeting inflammatory diseases through the innate immune system, with our ultimate aim being to uncover innovative therapies that combat diseases with significant unmet medical need.